Genprex Inc. (NASDAQ: GNPX)
$2.08
+0.1000 ( +5.05% ) 23.3K
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Market Data
Open
$2.08
Previous close
$1.98
Volume
23.3K
Market cap
$4.32M
Day range
$1.96 - $2.10
52 week range
$1.77 - $42.00
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 2 | Feb 21, 2024 |
4 | Insider transactions | 2 | Feb 21, 2024 |
4 | Insider transactions | 2 | Feb 21, 2024 |
8-k | 8K-related | 15 | Feb 05, 2024 |
8-k | 8K-related | 15 | Feb 02, 2024 |
8-k | 8K-related | 17 | Jan 31, 2024 |
8-k | 8K-related | 66 | Jan 05, 2024 |
8-k | 8K-related | 13 | Dec 18, 2023 |
8-k | 8K-related | 15 | Dec 13, 2023 |
10-q | Quarterly Reports | 43 | Nov 14, 2023 |